This is to inform that due to some circumstances beyond the organizer control, “2nd Edition of International Conference on Gastroenterology” (Gastro 2024) during October 21-23, 2024 at Baltimore, MD, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at gastroenterology@magnusconference.com or call + 1 (702) 988-2320.
A chronic bolus is a medical treatment that involves administering a continuous dose of medication or other substance over a period of time. This type of treatment is often used to treat chronic conditions or illnesses that require long-term management. Examples of conditions that may require a chronic bolus include diabetes, hypertension, and certain cancers. In a chronic bolus treatment, medication or other substances are delivered in a steady, continuous dose over a period of time. This dose is typically administered via a pump or other device that delivers the drug or substance directly into the patient’s body. The dosage may be adjusted as needed to manage the condition or illness, but the overall goal of the treatment is to provide a consistent, steady dose. The advantages of a chronic bolus treatment are that it is more effective than other methods of medication delivery in providing a consistent dose over time. This helps to ensure that the patient is receiving the required amount of medication or other substance. Additionally, this method eliminates the need for multiple injections or pills throughout the day, which can be inconvenient and uncomfortable for some patients. The disadvantages of chronic bolus treatment include the risk of developing side effects or other complications due to the long-term use of the medication or substance. Additionally, this method of delivery may be more expensive than other treatments. Overall, chronic bolus treatment is an effective and convenient way to deliver medications or other substances over a period of time. However, it is important to discuss the potential risks and benefits of this type of treatment with a healthcare provider prior to beginning therapy.
Title : Novel exosomal biomarkers for MASH
Aleksandra Leszczynska, University of California San Diego, United States
Title : Validation of GLAS (GP73+LG2m+Age+Sex) and ASAP (Age+Sex+AFP+PIVKA-II) algorithms for the management of liver fibrosis, cirrhosis and cancer
Philip M Hemken, Abbott Diagnostics Division R&D, United States
Title : Reverse multiple myeloma: First hepatic amyloidosis then multiple myeloma
Milaris M Sanchez Cordero, Mayaguez Medical Center, Puerto Rico
Title : Autophagy promotes the survival of adipose mesenchymal stem/stromal cells and enhances their therapeutic effects in cisplatin-induced liver injury via modulating TGF-1/Smad and PI3K/AKT signaling pathways
Eman Mohamad EL Nashar, King Khalid University, Saudi Arabia
Title : Epigastric Impedance measures gastric malfunction non-invasively. Time to revive it
John Andrew Sutton, Gastria Ltd, United Kingdom
Title : Digesting the connection: Exploring the psychological impact of gastroenterology issues on mental and emotional well being
Tracy E Hill, MGS Products LLC, United States